Morpholino imaging and therapy

Details Morpholino imaging and therapy Morpholino imaging and therapy

2005-05-31

2005-05-31

Hartley, Michael G. (Department: 1616)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001690, C424S001770, C424S009300, C424S009360, C424S009600, C514S231800

Reexamination Certificate

active

06899864

ABSTRACT:
The present invention provides a kit and a method for targeting of a diagnostic or therapeutic agent to a target site in a mammal having a pathological condition. The kit comprises, in separate containers, (a) a first conjugate comprising a targeting moiety and a Morpholino oligomer, wherein the targeting moiety selectively binds to a primary, target-specific binding site of the target site or to a substance produced by or associated with the target site; (b) optionally, a clearing agent; and (c) a second conjugate comprising a complementary Morpholino oligomer and a diagnostic agent or therapeutic agent. The method comprises administering (a), optionally (b), and (c) to a mammal.

REFERENCES:
patent: 3927193 (1975-12-01), Hansen et al.
patent: 4331647 (1982-05-01), Goldenberg
patent: 4348376 (1982-09-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4444744 (1984-04-01), Goldenberg
patent: 4460459 (1984-07-01), Shaw et al.
patent: 4460561 (1984-07-01), Goldenberg
patent: 4468457 (1984-08-01), Goldenberg et al.
patent: 4474893 (1984-10-01), Reading
patent: 4479895 (1984-10-01), Auditore-Hargreaves
patent: 4624846 (1986-11-01), Goldenberg
patent: 4782840 (1988-11-01), Martin, Jr. et al.
patent: 4818709 (1989-04-01), Primus et al.
patent: 4863713 (1989-09-01), Goldwin et al.
patent: 4932412 (1990-06-01), Goldenberg
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5185444 (1993-02-01), Summerton et al.
patent: 5482698 (1996-01-01), Griffiths
patent: 5645985 (1997-07-01), Froehler et al.
patent: 5698685 (1997-12-01), Summerton et al.
patent: 5716595 (1998-02-01), Goldenberg
patent: 5874540 (1999-02-01), Hansen et al.
patent: 5958408 (1999-09-01), Griffiths et al.
patent: 6331175 (2001-12-01), Goldenberg
Barbet, J. et el., “Pretargeting with the Affinity Enhancement System for Radioimmunotherapy”,Cancer Biootheraphy&Radiopharmaceuticals:vol. 14; No. 3:153-166 (1999).
Childs, R. L. et al., “Optimum Conditions for Labeling of DTPA-Coupled Antibodies with Technetium-99m,”J. Nuc. Med.; vol. 26; No. 3:293-299 (1985).
Crooke, R.M. et al., “Metabolism of Antisense Oligonucleotides in Rat Liver Homogenates,”J. Pharmacology and Experimental Therapeutics: vol. 292; No. 1:140.149 (2000).
Gautherot, E. et al., “Pretargeted Radioimmunotherapy of Human Colorectal Xenografts with Bispecific antibody and131I-Labeled bivalent Hapten,”Journal of Nuclear Medicne: vol. 41; No. 3:480-487 (2000).
Gestin, J.F. et al., “Two-Step Targeting of Xenografted colon Carcinoma Using a Bispecific Antibody and188Re-Labeled Bivalent Hapten: Biodistribution and Dosimetry Studies,”Journal of Nuclear Medicine: vol. 42; No. 1:146-153 (2001).
Goodwin el al., “Pre-Targeted immunoscintigraphy of Murine Tumors with Indium-111-Labeled Bifunctional Haptens,”Journal of Nuclear Medicine: vol. 29, No. 1:226-234 (1988).
Hansen et al., “Characterization of Second-Generation Monocolonal Antibodies Against Carcinoembryonic Antigen,”Cancer: vol. 71, No. 11:3478-3485 (1993).
Hnatowich et al., “Investigations of Avidin and Biotin for Imaging Applications,”Journal of Nuclear Medicine: vol. 28, No. 8:1294-1302 (1987).
Hnatowich, D.J., “antisense and Nuclear Medicine,”Journal of Nuclear Medicine: vol. 40, No. 4:693-703 (1999).
Kalofonos et al., “Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin- Conjugated Antibodies: Preliminary Communication,”Journal of Nuclear Medicine: vol. 31:1791-1796 (1990).
Karacay. H. et al., “Experimental Pretargeting Studies of Cancer with a Humanized anti-CEA x Murine anti- [ln-DTPA] Bispecific Antibody Construct and a99mTc-/188Re-Labeled Peptide,”Bioconjugate Chem., vol. 11, No. 6: 842-854 (2000).
Kaukinen, U. et al., “The reactivity of phosphodiester bonds within linear single-stranded oligoribonucleotides is strongly dependent on the base sequence,”Nucleic Acids Research: vol. 30; No. 2:468-474 (2002).
Kllbanov et al., “Blood Clearance of Radiolabeled Antibody: Enhancement by Lactosamination and Treatment with Biotin-Avidin or Anti-Mouse,”Journal of Nuclear Medicine: vol. 29, No. 12:1951-1956 (1988).
Liu G. et al., “Tumor Pretargeting in Mice Using99mTc-Labeled Morpholino, a DNA Analog,”Journal Nuclear Medicine: vol. 43, No. 3:384-391 (2002).
Lubic, S.P. et al., “Biodistribution and Dosimetry of Pretargeted Monoclonal Antibody 2D12.5 and Y-Janus-DOTA in BALB/c Mice with KHJJ Mouse Adenocarcinoma,”Journal Nuclear Medicine: vol. 42, No. 4:670-678 (2001).
Mang'era, K., et al., “Initial Investigations of99mTc-IabeIed morpholinos for radiopharmaceutical applications,”European Journal of Nuclear Medicine: vol. 28, No. 11:1682-1689 (2001).
Mardirossian, G. et al., “In Vivo Hybridization of Technetium-99m-Labeled Peptide Nucleic Acid (PNA),”Journal of Nuclear Medicine: vol. 38; No. 6:907-913 (1997).
Milstein et al., “Hybrid hybridomas and the production of bi-specific monoclonal antibodies,”Immunology Today: vol. 5, No. 10:299-304 (1984).
Morassutti, C. et al., “Effect of Oligomer Length and Base Substitutions on the Cytotoxic Activity and Specific Nuclear Protein Recognition of GTn Oligonucleotides in the Human Leukemic CCRF-CEM Cell Line,”Nucleosides & Nucleotides; vol. 18:1711-1716 (1999).
Oehr et al., “Streptavidin and Biotin as Potential Tumor Imaging,”Journal of Nuclear Medicine: vol. 29, No. 5:728-729 (1988).
Paganelli et al., “Three-Step Monoclonal Antibody tumar Targeting in Carcinoembryonic Antigen-positive Patients,”Cancer Research: vol. 51:5960-5966 (1991).
Paganelli et al., “Monoclonal Antibody pretargetting Techniques for Tumour Localization: the Avidin-biotin System,”Nuclear Medicine Communication: vol. 12:211-234 (1991).
Rusckowski et al., “Pretargeting Using Peptide Nucleic Acid,”Cancer: vol. 80, No. 12:2699-2705 (1997).
Schechter et al., “Indirect Immunotargeting of CIS-PT to Human Epidermoid Carcinoma KB Using the Avidin-Biotin System.”Int. J. Cancer: vol. 48:167-172 (1991).
Shafer, R.H. et al., “Biological Aspects of DNA/RNA Quadruplexes,”Biopoly(Nucleic Acid Sci.): vol. 56:209-227 (2001).
Sinitsyn et al., “Rapid Blood clearance of Biotinylated IgG After Infusion of Avidin,”Journal of Nuclear Medicine: vol. 30, No. 1:66-69 (1989).
Stickney et al., “Bifunctional Antibody: A binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma,”Cancer Research: vol. 51:6650-6655 (1991).
Summerton et al., Review Article: Morpholino antisense Oligomers: Design, Preparation, and Properties,Antisense Nucleic Acid Drug Development: vol. 7:187-195 (1997).
Wang, G. et al., “Defining the Peptide Nucleic Acids (PNA) Length Requirement for PNA Binding-Induced Transcription and Gene Expression,”Journal Molecular Biology: vol. 313:933-940 (2001).
Wang, Y. et al. “Pretargeting with Amplification Using Polymeric Peptide Nucleic Acid,”Bioconjugate Chem.: vol. 12:807-816 (2001).
Winnard, P. et al., “Preparation and Use of NHS-MAG3for Technetium-99m Labeling of DNA,”Nuclear Medicine&Biology: vol. 24:425-432 (1997).
Yuan et al., “Pharmacokinetic Analysis of Two-Step Approaches Using Bifunctional and Enzyme- Conjugated Antibodies1,”Cancer Research: vol. 51:3119-3130 (1991).
Zhang, Y.M. et al., “Influence of Different Chelators (HYNIC, MAG3 and DTPA) on Tumor Cell Accumulation and Mouse Biodistribution of Technetium-99m Labeled to Antisense DNA,”European Journal of Nuclear Medicine: vol. 27:1700-1707 (2000).
Zhao, Q. et al., “Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in Mice,”Antisense&Nucleic Acid Drug Development: vol. 7:495-502 (1997).
Zhu, H. et al., “Tumor Pretargeting for

Affiliated with

Also associated with

Rating

Morpholino imaging and therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Morpholino imaging and therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Morpholino imaging and therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3370124